Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 1, 2022, reports a material definitive agreement entered into by Precigen, Inc. (the "Company"). The filing details the sale of the Company's wholly-owned subsidiary, Trans Ova Genetics, L.C. ("Trans Ova"), to Spring Bidco LLC ("Buyer").
Key Financial Metrics and Transaction Terms
- Total Consideration: $170 million in cash payable at closing (subject to working capital adjustments) plus up to $10 million in earn-out payments over two years.
- Transaction Value: Up to $180 million total potential consideration.
- Use of Proceeds: The Company intends to hold $200 million (including purchase price and additional funds) in a segregated account to resolve outstanding convertible bonds and for other permitted purposes.
- Termination Fee: Buyer is obligated to pay a termination fee of $12,750,000 to the Company if the transaction fails to close due to the failure of the HSR Act waiting period to expire.
- Financial Statements: This filing does not provide revenue, profit, cash flow, or margin data for the Company or Trans Ova.
Material Changes and Transaction Status
The primary material change is the commitment to divest 100% of the membership interests of Trans Ova. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions including:
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
- Absence of court injunctions prohibiting the transaction.
- No material adverse effect on Trans Ova's business or assets.
- Accuracy of representations and warranties and compliance with covenants.
A guarantee has been executed by Houdstermaatschappij Wilg B.V. to ensure the Buyer fulfills all payment obligations.
Guidance, Outlook, and Risks
Management expects the transaction to close in Q3 2022. The Company has issued forward-looking statements regarding the use of capital from the transaction to support its CAR-T and AdenoVerse therapy portfolios. Key risks and contingencies include:
- Closing Risk: The sale may not be consummated on the expected timeline or at all due to regulatory delays (HSR Act) or failure to satisfy other conditions.
- Operational Risk: Potential impacts on clinical trial timelines due to the COVID-19 pandemic.
- Termination Risk: The agreement includes termination rights if the transaction is not completed by July 1, 2023, or if a material breach is not cured within 45 days.
Investor Verification Checklist
- Verify the status of the HSR Act waiting period and any other required regulatory consents.
- Confirm the exact amount of outstanding convertible bonds to be resolved with the proceeds.
- Monitor for any material adverse effects on Trans Ova's operations prior to closing.
- Review the specific terms of the earn-out mechanism for the potential $10 million additional payment.
- Check for any updates regarding the termination fee conditions if the deal fails to close.